VistaGen stock rises after completing Phase 3 trial for anxiety drug By Investing.com
Update: 2025-11-03
Description
VistaGen Therapeutics makes significant progress in developing a new anxiety treatment, fasedienol, which showed promising results in a Phase Three clinical trial. This intranasal medicine could offer a faster, more targeted solution for social anxiety, potentially becoming the first on-the-spot treatment approved by the FDA. With positive results expected soon, millions of Americans living with social anxiety are watching closely for this potential breakthrough.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel




